Azithromycin and Hydroxychloroquine Accelerate Recovery of Outpatients with Mild/Moderate COVID-19
Violaine Guérin, Pierre Lévy, Jean-Louis Thomas, Thierry Lardenois, Philippe Lacrosse, Emmanuel Sarrazin, Natacha Regensberg-de Andreis, Martine Wonner
Asian Journal of Medicine and Health · pp. 45–55 · Published 15 Jul 2020
10.9734/ajmah/2020/v18i730224Abstract
Aims: The challenge regarding COVID-19 is to prevent complications and fatal evolution. Azithromycin (AZM) and hydroxychloroquine (HCQ) have proven their antiviral effect in vitro. We aimed to assess the efficacy and safety of AZM alone or combined to HCQ, prescribed, at an early stage, in patients with Covid-19, in a primary care setting. Study Design: Retrospective observational study. Place and Duration of Study: Patients have been followed by private practitioners in France, between March and April 2020. Methodology: Eighty-eight patients received either no or a symptomatic treatment (NST) (n=34) or AZM alone (n=34) or AZM+HCQ (n=20). The efficacy end point was the time to clinical recovery and the safety end point was the occurrence of cardiovascular events. To improve the evidence level, a case-control analysis was performed on a sample of 57 patients (19/group) matched for age, sex and BMI. Results: The mean (SD) times to achieve clinical recovery were respectively 25.8 days (11.1), 12.9 days (13.4) and 9.2 days (9.3), showing a statistically significant difference between NST and AZM alone (p<0.0001) or AZM+HCQ (p<0.0001). The statistical difference between NST and AZM was confirmed (p=0.0149) as well as the difference with AZM+HCQ (p=0.0002). No cardiac toxicity was recorded in any patient. No statistical difference was shown between AZM and AZM+HCQ groups, although the dual therapy tended to be more effective in patients over 50 years, based on an analysis using the cox model. Conclusion: AZM and AZM+HCQ favourably impacted the course of the disease. We need trials, ideally prospective/double blind, to show if a statistical difference can be evidenced with a broader group, and clarify the indications of each treatment depending on initial clinical presentation.
References (22)
- 1 Clinical Characteristics of Coronavirus Disease 2019 in China [DOI]
- 2 Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro [DOI]
- 3 RETRACTED: Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial [DOI]
- 4 In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) [DOI]
- 5 Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies [DOI]
- 6 Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro [DOI]
- 7 Chloroquine is a potent inhibitor of SARS coronavirus infection and spread [DOI]
- 8 Clinical and microbiological effect of a combination of hydroxychloroquine and azithromycin in 80 COVID-19 patients with at least a six-day follow up: A pilot observational study [DOI]
- 9 In vitro inhibition of severe acute respiratory syndrome coronavirus by chloroquine [DOI]
- 10 New insights into the antiviral effects of chloroquine [DOI]
- 11 Treatment with hydroxychloroquine, azithromycin, and combination in patients hospitalized with COVID-19 [DOI]
- 12 Early treatment of COVID-19 patients with hydroxychloroquine and azithromycin: A retrospective analysis of 1061 cases in Marseille, France [DOI]
- 13 Mechanism of action of hydroxychloroquine as an antirheumatic drug [DOI]
- 14 Anti-malaria drug chloroquine is highly effective in treating avian influenza A H5N1 virus infection in an animal model [DOI]
- 15 Effect of Chloroquine, Hydroxychloroquine, and Azithromycin on the Corrected QT Interval in Patients With SARS-CoV-2 Infection [DOI]
- 16 Outcomes of 3,737 COVID-19 patients treated with hydroxychloroquine/azithromycin and other regimens in Marseille, France: A retrospective analysis [DOI]
- 17 Efficacy of chloroquine and hydroxychloroquine in the treatment of COVID-19. [DOI]
- 18 Optimizing Hydroxychloroquine Dosing for Patients With COVID‐19: An Integrative Modeling Approach for Effective Drug Repurposing [DOI]
- 19 Azithromycin induces anti-viral effects in cultured bronchial epithelial cells from COPD patients [DOI]
- 20 Emerging prophylaxis strategies against COVID-19 [DOI]
- 21 Efficacy of hydroxychloroquine in patients with COVID-19: results of a randomized clinical trial [DOI]
- 22 Treatment Response to Hydroxychloroquine, Lopinavir–Ritonavir, and Antibiotics for Moderate COVID-19: A First Report on the Pharmacological Outcomes from South Korea [DOI]
Cited by 52
Alberto Boretti · Asian Journal of Chemistry · 2021
Thibault Fiolet, Anthony Guihur, Mathieu Edouard Rebeaud · Clinical Microbiology and Infection · 2021
C. Prodromos, T. Rumschlag · New Microbes and New Infections · 2020
Percy Soto-Becerra, Carlos Culquichicón, Yamilee Hurtado-Roca · 2020
Andrew Ip, Jaeil Ahn, Yizhao Zhou · 2020
Daniel Echeverría-Esnal, Clara Martin-Ontiyuelo, María Eugenia Navarrete-Rouco · Expert Review of Anti-infective Therapy · 2020
Philippe Gautret, Matthieu Million, Pierre-André Jarrot · Expert Review of Clinical Immunology · 2020
Georgia G. Kournoutou, George Dinos · Antibiotics · 2022
Andrew Ip, Jaeil Ahn, Yizhao Zhou · BMC Infectious Diseases · 2021
Roberto Alfonso Accinelli, Grisel Jesús Ynga-Meléndez, Juan Alonso León-Abarca · Travel Medicine and Infectious Disease · 2021
Showing 20 of 52 known citations — external sources report more than can currently be individually listed.
Related research
- Covid-2019:“A Microbiological Monster” — shares topic coverage
- COVID 19 Disease Caused by Coronavirus 2 (SARS-CoV-2) (Severe Acute Respiratory Syndrome) — shares topic coverage
- Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2): What Can Africa Learn from Ongoing Research in Epidemiology, Clinical Manifestations, Chemotherapy and Prevention? — shares topic coverage
- Early Treatment with Hydroxychloroquine Improves Clinical Outcomes and Reduces Hospital Admissions in COVID-19 Associated Pneumonia — shares topic coverage
- A Review on Intranasal Covid Vaccines for SARS-CoV-2 — shares topic coverage
Article metrics
Real usage data collected on this platform.
127
Page views
0
PDF downloads
33
Outbound clicks
52
Citations
Views over time
Views by country
Approximate, from request IP at view time — not citizenship or institution. Countries with fewer than 5 views are grouped as "Other".
Traffic sources
Referring site, by host.
Views and downloads exclude known bots/crawlers. Citations combines this platform's own DOI-resolved index with each external source's own reported total — see Cited by above for individually listed citing works. Last refreshed 0 seconds ago.